Aflac Incorporated's SEC filings document a supplemental health and life insurer with reportable operations in Japan and the United States. Form 8-K reports furnish quarterly and annual results, supplemental earnings materials, investor presentations and Regulation FD disclosures tied to segment performance, premiums, investment income, dividends and share repurchases.
Proxy and annual-meeting filings cover board elections, executive compensation votes, auditor ratification, shareholder proposals and common-stock voting matters. Other material-event filings describe financing arrangements, including pre-capitalized trust securities and contingent senior-note funding, as well as cybersecurity incident disclosures, operational continuity, customer information risks, governance controls and public-company reporting obligations.
A holder of AFL common stock has filed a Form 144 notice indicating an intent to sell 786 common shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/17/2025. The filing lists an aggregate market value of 114,000.00 for a prior sale of 1,000 shares on 11/07/2025 and shows 524,113,917 common shares outstanding for the issuer.
The shares to be sold were acquired via a stock option granted on 05/07/2018 and paid for in cash on 11/17/2025. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations, as required by the Form 144 certification.
Aflac (AFL) filed a Form 144 indicating a proposed sale of restricted or control securities under Rule 144. The filer plans to sell 3,452 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, reflecting an aggregate market value of $397,325.20. The shares were acquired via stock options granted on 02/09/2016 and exercised for cash on 11/14/2025. Aflac had 524,113,917 shares outstanding at the time listed in the notice. Form 144 is a notice of intent and does not guarantee that a sale will occur.
Aflac Incorporated (AFL) reported an insider transaction by its Sr. EVP and CFO, Max K. Broden. On 11/10/2025, he exercised employee stock options (transaction code M) to acquire 4,668 shares of common stock at an exercise price of $38.755 per share.
Following this transaction, his beneficial ownership stands at 135,021 shares held directly and 339 shares held indirectly through his spouse. The options were part of a grant that vested in three tranches during 2018–2020 and carry an expiration date of 06/26/2027.
Aflac (AFL) insider filing: Senior Executive Vice President Audrey B. Tillman reported a bona fide gift of 26,970 shares of Aflac common stock on 11/07/2025 (Transaction Code G) at a reported price of $0.
After the transaction, she beneficially owned 230,688 shares directly. She also reported 17,899 shares held indirectly through a 401(k) Plan and 9 shares held indirectly by children.
Aflac Inc. (AFL) director Joseph L. Moskowitz reported an open‑market sale of 1,000 shares of common stock at $114 on 11/07/2025.
Following the sale, he beneficially owns 23,615 shares, held directly. The transaction was executed pursuant to a Rule 10b5‑1 trading plan adopted on 12/04/2024.
Aflac (AFL) reported an insider stock sale by EVP, COO & CFO, Aflac U.S., Frederic Simard. On 11/06/2025, he sold 1,722 shares of common stock at $112.50 per share. Following the transaction, he beneficially owns 1,364 shares directly and 589 shares indirectly through a 401(k) plan.
Aflac (AFL) received a Form 144 notice for a proposed sale of 1,000 common shares with an aggregate market value of $114,000. The filing lists Fidelity Brokerage Services LLC as broker and the NYSE as the exchange, with an approximate sale date of 11/07/2025.
The shares were acquired through restricted stock vesting from the issuer on 05/03/2023 (121), 05/19/2023 (478), and 05/01/2024 (401). Shares outstanding were 524,113,917. In the past three months, Joseph Moskowitz sold 1,000 shares on 08/08/2025 for $102,570.
AFL filed a Form 144 notice for a proposed sale under Rule 144. The seller plans to sell 1,722 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $193,725 and an approximate sale date of 11/06/2025.
The shares come from restricted stock vesting awards: 852 shares on 09/15/2024 and 870 shares on 09/15/2025, received as compensation. Shares outstanding were 524,113,917.
Aflac Inc filed a Form 13F holdings report disclosing a total reported value of $161,407,584 across 3 information-table entries. The filing is signed by Robin Blackmon, SVP and Chief Accounting Officer, on 11-05-2025. The report lists Aflac Asset Management LLC as an included manager.
Aflac Incorporated reported strong results for the quarter ended September 30, 2025. Total revenues were $4.74 billion, up from $2.95 billion a year earlier, helped by higher net investment income and a swing to $275 million of net investment gains from a $(1.41) billion loss.
Net earnings rose to $1.64 billion from a loss of $93 million, and diluted earnings per share climbed to $3.08 from $(0.17). Reserve remeasurement gains reduced benefits and claims, supporting margins in both Aflac Japan and Aflac U.S.
For the first nine months of 2025, net earnings were $2.27 billion on revenues of $12.30 billion. Operating cash flow was solid at $2.24 billion, and cash and cash equivalents increased to $6.77 billion. Shareholders’ equity grew to $28.69 billion, reflecting higher retained earnings and favorable discount rate effects in other comprehensive income, partly offset by significant share repurchases and dividends.